CytoMed Therapeutics Insider Plans $171k Share Sale per Form 144

Rhea-AI Filing Summary

CytoMed Therapeutics Limited (NASDAQ: GDTC) has filed a Form 144 indicating the proposed sale of 81,482 ordinary shares, valued at roughly $171,112 based on the market price disclosed in the filing. The seller—whose name is not provided in the excerpt—plans to execute the transaction through Bank of Singapore on or about 23 June 2025. The company has 11.54 million shares outstanding, so the notice represents approximately 0.7 % of total shares.

The securities were originally acquired via a share subscription on 22 April 2021. The filing also discloses that the same holder has sold 4,928 shares over the past three months, generating aggregate gross proceeds of $11,548.72. No adverse, non-public information is claimed to be known by the seller, as required under Rule 144 representations.

While Form 144 filings do not guarantee that a sale will occur, they signal the intent of an affiliate or insider to liquidate shares. Investors often monitor such filings as a gauge of insider sentiment and potential stock-supply overhang. The transaction size is modest relative to the public float, but it may still weigh on short-term sentiment given GDTC’s limited trading volume as a small-cap biotech.

Positive

• None.

Negative

• Insider selling signal: Proposed sale of 81,482 shares may indicate reduced confidence or create supply overhang.
• Ongoing share disposals: Additional 4,928 shares already sold in the past three months reinforce selling trend.

Insights

Equity Analyst

TL;DR: Insider plans to sell 0.7 % of GDTC shares; small but can pressure near-term sentiment.

The Form 144 reveals an affiliate’s intention to dispose of 81,482 shares, worth about $171k. Although the stake equals less than 1 % of shares outstanding, GDTC’s thin float means incremental supply can affect pricing. Recent dribble-out sales (≈5 k shares) support a pattern of continued liquidation. Absent earnings or operational news, the filing is modestly negative for short-term momentum but immaterial to long-term fundamentals.

Corporate Governance Specialist

TL;DR: Routine Rule 144 filing; no red flags beyond typical insider liquidity move.

Rule 144 compliance appears standard: prior holding period met, broker identified, and prior-month sales disclosed. No information on relationship to issuer limits assessment of potential conflicts, but the size and cadence of sales do not indicate a broad insider exodus. Governance risk is therefore low; impact is principally market-liquidity related.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Bank of Singapore 63 Market St, #22-00 Singapore U0 048942	81482	171112.00	11540000	06/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	04/22/2021	Share Subscription	Issuer			711822	04/20/2021	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	05/27/2025	650	1547.06
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	05/28/2025	1876	4409.34
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	05/29/2025	1761	4088.73
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	06/02/2025	520	1218.39
mDR Ltd. 53 Ubi Crescent Singapore U0 408594	Ordinary Shares	06/03/2025	121	285.20

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many CytoMed Therapeutics (GDTC) shares are proposed for sale under this Form 144?

The filing covers 81,482 ordinary shares.

What percentage of GDTC’s outstanding shares does 81,482 represent?

Approximately 0.7 % of the 11.54 million shares outstanding.

When is the anticipated sale date for the GDTC shares?

The filer listed an approximate sale date of 23 June 2025.

Which broker is handling the proposed GDTC share sale?

The shares are to be sold through Bank of Singapore.

Have any GDTC shares been sold recently by the same filer?

Yes, 4,928 shares were sold between 27 May and 3 June 2025 for total proceeds of $11,548.72.